Page 672 - Hematology_ Basic Principles and Practice ( PDFDrive )

570.e4 Part V Red Blood Cells

155. Harmatz P, Butensky E, Quirolo K, et al: Severity of iron overload 182. Engle MA, Erlandson M, Smith CH: Late cardiac complications of
in patients with sickle cell disease receiving chronic red blood cell chronic, severe, refractory anemia with hemochromatosis. Circulation
transfusion therapy. Blood 96:76, 2000. 30:698, 1964.
156. Kushner JP, Porter JP, Olivieri NF: Secondary iron overload. Hematology 183. Olivieri NF, Nathan DG, MacMillan JH, et al: Survival in medically
Am Soc Hematol Educ Program 47, 2001. treated patients with homozygous beta-thalassemia. N Engl J Med
157. Hoffbrand AV, Gorman A, Laulicht M, et al: Improvement in iron 331:574, 1994.
status and liver function in patients with transfusional iron overload 184. Davis BA, O’Sullivan C, Jarritt PH, et al: Value of sequential monitoring
with long-term subcutaneous desferrioxamine. Lancet 1:947, 1979. of left ventricular ejection fraction in the management of thalassemia
158. Cohen A, Martin M, Schwartz E: Response to long-term deferoxamine major. Blood 104:263, 2004.
therapy in thalassemia. J Pediatr 99:689, 1981. 185. Anderson LJ, Westwood MA, Holden S, et al: Myocardial iron clear-
159. Modell B, Letsky EA, Flynn DM, et al: Survival and desferrioxamine ance during reversal of siderotic cardiomyopathy with intravenous
in thalassaemia major. Br Med J (Clin Res Ed) 284:1081, 1982. desferrioxamine: a prospective study using T2* cardiovascular magnetic
160. Wolfe L, Olivieri N, Sallan D, et al: Prevention of cardiac disease by resonance. Br J Haematol 127:348, 2004.
subcutaneous deferoxamine in patients with thalassemia major. N Engl 186. Engle MA: Cardiac involvement in Cooley’s anemia. Ann N Y Acad Sci
J Med 312:1600, 1985. 119:694, 1964.
161. Maurer HS, Lloyd-Still JD, Ingrisano C, et al: A prospective evaluation 187. Ehlers KH, Levin AR, Markenson AL, et al: Longitudinal study of
of iron chelation therapy in children with severe beta-thalassemia: A cardiac function in thalassemia major. Ann N Y Acad Sci 344:397,
six-year study. Am J Dis Child 142:287, 1988. 1980.
162. Olivieri N: Thalassaemia: clinical management. Baillieres Clin Haematol 188. Giardina PJ, Ehlers KH, Engle MA, et al: The effect of subcutaneous
11:147, 1998. deferoxamine on the cardiac profile of thalassemia major: a five-year
163. Piomelli S, Graziano J, Karpatkin M, et al: Chelation therapy, transfu- study. Ann N Y Acad Sci 445:282, 1985.
sion requirement, and iron balance in young thalassemic patients. Ann 189. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al: Survival and
N Y Acad Sci 344:409, 1980. disease complications in thalassemia major. Ann N Y Acad Sci 850:227,
164. De Virgiliis S, Cossu P, Toccafondi C, et al: Effect of subcutaneous 1998.
desferrioxamine on iron balance in young thalassemia major patients. 190. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al: Survival and com-
Am J Pediatr Hematol Oncol 5:73, 1983. plications in patients with thalassemia major treated with transfusion
165. Fargion S, Taddei MT, Gabutti V, et al: Early iron overload in beta- and deferoxamine. Haematologica 89:1187, 2004.
thalassaemia major: when to start chelation therapy? Arch Dis Child 191. Gabutti V, Piga A: Results of long-term iron-chelating therapy. Acta
57:929, 1982. Haematol 95:26, 1996.
166. Russo G, Romeo MA, Musumeci S, et al: Early iron chelation therapy 192. Cunningham MJ, Macklin EA, Neufeld EJ, et al: Complications of
in thalassemia major. Haematologica 68:69, 1983. beta-thalassemia major in North America. Blood 104:34, 2004.
167. De Virgiliis S, Congia M, Frau F, et al: Deferoxamine-induced growth 193. Cohen A, Martin M, Schwartz E: Depletion of excessive liver iron stores
retardation in patients with thalassemia major. J Pediatr 113:661, 1988. with desferrioxamine. Br J Haematol 58:369, 1984.
168. Olivieri NF, Koren G, Harris J, et al: Growth failure and bony changes 194. Cohen A, Mizanin J, Schwartz E: Treatment of iron overload in Cooley’s
induced by deferoxamine. Am J Pediatr Hematol Oncol 14:48, 1992. anemia. Ann N Y Acad Sci 445:274, 1985.
169. Brill PW, Winchester P, Giardina PJ, et al: Deferoxamine-induced bone 195. Cohen A, Cohen IJ, Schwartz E: Scurvy and altered iron stores in
dysplasia in patients with thalassemia major. AJR Am J Roentgenol thalassemia major. N Engl J Med 304:158, 1981.
156:561, 1991. 196. Kolnagou A, Economides C, Eracleous E, et al: Low serum ferritin
170. Porter JB, Jaswon MS, Huehns ER, et al: Desferrioxamine ototoxicity: levels are misleading for detecting cardiac iron overload and increase
evaluation of risk factors in thalassaemic patients and guidelines for safe the risk of cardiomyopathy in thalassemia patients. The importance of
dosage. Br J Haematol 73:403, 1989. cardiac iron overload monitoring using magnetic resonance imaging T2
171. Olivieri NF, Buncic JR, Chew E, et al: Visual and auditory neurotoxic- and T2*. Hemoglobin 30:219, 2006.
ity in patients receiving subcutaneous deferoxamine infusions. N Engl J 197. Kolnagou A, Kontoghiorghes GJ: Effective combination therapy of
Med 314:869, 1986. deferiprone and deferoxamine for the rapid clearance of excess cardiac
172. Athanasion A, Shepp MA, Necheles TF: Anaphylactic reaction to IRON and the prevention of heart disease in thalassemia. The Protocol
desferrioxamine. Lancet 2:616, 1977. of the International Committee on Oral Chelators. Hemoglobin 30:239,
173. Batey R, Scott J, Jain S, et al: Acute renal insufficiency occurring during 2006.
intravenous desferrioxamine therapy. Scand J Haematol 22:277, 1979. 198. O’Brien RT: Ascorbic acid enhancement of desferrioxamine-induced
174. Bousquet J, Navarro M, Robert G, et al: Rapid desensitisation for urinary iron excretion in thalassemia major. Ann N Y Acad Sci 232:221,
desferrioxamine anaphylactoid reaction. Lancet 2:859, 1983. 1974.
175. Miller KB, Rosenwasser LJ, Bessette JA, et al: Rapid desensitisation for 199. Bridges KR, Hoffman KE: The effects of ascorbic acid on the intracel-
desferrioxamine anaphylactic reaction. Lancet 1:1059, 1981. lular metabolism of iron and ferritin. J Biol Chem 261:14273, 1986.
176. Freedman MH, Grisaru D, Olivieri N, et al: Pulmonary syndrome in 200. Bridges KR: Ascorbic acid inhibits lysosomal autophagy of ferritin. J
patients with thalassemia major receiving intravenous deferoxamine Biol Chem 262:14773, 1987.
infusions. Am J Dis Child 144:565, 1990. 201. Miller DM, Aust SD: Studies of ascorbate-dependent, iron-catalyzed
177. Gallant T, Freedman MH, Vellend H, et al: Yersinia sepsis in patients lipid peroxidation. Arch Biochem Biophys 271:113, 1989.
with iron overload treated with deferoxamine. N Engl J Med 314:1643, 202. Burkitt MJ, Gilbert BC: The control of iron-induced oxidative damage
1986. in isolated rat-liver mitochondria by respiration state and ascorbate. Free
178. Green NS: Yersinia infections in patients with homozygous beta- Radic Res Commun 5:333, 1989.
thalassemia associated with iron overload and its treatment. Pediatr 203. Link G, Athias P, Grynberg A, et al: Effect of iron loading on trans-
Hematol Oncol 9:247, 1992. membrane potential, contraction, and automaticity of rat ventricular
179. Cunningham M, Macklin E: Successful pregnancy in thalassemia major muscle cells in culture. J Lab Clin Med 113:103, 1989.
women in the thalassemia clinical research network, 2004, American 204. Nienhuis AW: Safety of intensive chelation therapy. N Engl J Med
Society of Pediatric Hematology Oncology (Abstract). 296:114, 1977.
180. De Sanctis V, D’Ascola G, Wonke B: The development of diabetes mel- 205. Hider RC, Singh S, Porter JB, et al: The development of hydroxypyridin-
litus and chronic liver disease in long term chelated beta thalassaemic 4-ones as orally active iron chelators. Ann N Y Acad Sci 612:327,
patients. Postgrad Med J 62:831, 1986. 1990.
181. Marcus RE, Davies SC, Bantock HM, et al: Desferrioxamine to 206. Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV, et al: Effective chela-
improve cardiac function in iron-overloaded patients with thalassemia tion of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-
major. Lancet 1:392, 1984. 3-hydroxypyrid-4-one. Br Med J (Clin Res Ed) 295:1509, 1987.